---
title: "Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292932773.md"
description: "H.C. Wainwright analyst Joseph Pantginis reaffirmed a Buy rating on Adlai Nortye with a $20 price target, citing the strategic advancement of its AN9025 dual-arm clinical strategy. The intermittent weekly dosing arm, supported by preclinical data showing sustained tumor control, aims to improve the therapeutic window and manage toxicity. This approach addresses class-wide safety constraints of pan-RAS inhibitors, reinforcing confidence in the company's pipeline and long-term value."
datetime: "2026-07-16T16:45:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292932773.md)
  - [en](https://longbridge.com/en/news/292932773.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292932773.md)
---

# Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Adlai Nortye Ltd. Sponsored ADR, with a price target of $20.00.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Joseph Pantginis has given his Buy rating due to a combination of factors, notably the strategic advancement of AN9025 into an intermittent weekly dosing arm alongside the ongoing daily regimen. He views this dual-arm Phase 1 design as expanding the program’s opportunities, while the unchanged $20 price target reflects confidence that this broader clinical approach can enhance the asset’s long-term value.

Pantginis highlights that the weekly schedule is grounded in preclinical data showing sustained tumor control even during drug holidays, supporting a hypothesis of improved therapeutic window and manageable toxicity. He also underscores that Adlai Nortye is tackling the class-wide safety constraints of pan-RAS(ON) inhibitors through both innovative scheduling with AN9025 and targeted delivery via its RASiCA-based ADC AN4035, reinforcing his constructive outlook on the company’s pipeline and risk-reward profile.

### Related Stocks

- [ANL.US](https://longbridge.com/en/quote/ANL.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)

## Related News & Research

- [Adlai Nortye wins Australian HREC approval for AN4035 phase 1 trial](https://longbridge.com/en/news/294682603.md)
- [Adlai Nortye director Lars Erik Birgerson files initial beneficial ownership statement](https://longbridge.com/en/news/294843208.md)
- [Avalo Therapeutics posts corporate deck spotlighting IL-1β inhibitor pipeline for hidradenitis suppurativa](https://longbridge.com/en/news/295098964.md)
- [Corvus publishes corporate presentation highlighting soquelitinib ITK inhibitor pipeline in immune disease and T-cell malignancies](https://longbridge.com/en/news/295155153.md)
- [China NMPA approves TransThera’s Yochanra for FGFR inhibitor-resistant cholangiocarcinoma](https://longbridge.com/en/news/295190692.md)